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Abstract
Background: Reducing the burden of disease relies on availability of evidence-based clinical practice guidelines
(CPGs). There is limited data on availability, quality and content of guidelines within the Southern African
Development Community (SADC). This evaluation aims to address this gap in knowledge and provide
recommendations for regional guideline development.
Methods: We prioritised five diseases: HIV in adults, malaria in children and adults, pre-eclampsia, diarrhoea in
children and hypertension in primary care. A comprehensive electronic search to locate guidelines was conducted
between June and October 2010 and augmented with email contact with SADC Ministries of Health. Independent
reviewers used the AGREE II tool to score six quality domains reporting the guideline development process.
Alignment of the evidence-base of the guidelines was evaluated by comparing their content with key
recommendations from accepted reference guidelines, identified with a content expert, and percentage scores
were calculated.
Findings: We identified 30 guidelines from 13 countries, publication dates ranging from 2003-2010. Overall the
‘scope and purpose’ and ‘clarity and presentation’ domains of the AGREE II instrument scored highest, median 58%
(range 19-92) and 83%(range 17-100) respectively. ‘Stakeholder involvement’ followed with median 39%(range 6-75).
‘Applicability’, ‘rigour of development’ and ‘editorial independence’ scored poorly, all below 25%. Alignment with
evidence was variable across member states, the lowest scores occurring in older guidelines or where the
guideline being evaluated was part of broader primary healthcare CPG rather than a disease-specific guideline.
Conclusion: This review identified quality gaps and variable alignment with best evidence in available guidelines
within SADC for five priority diseases. Future guideline development processes within SADC should better adhere
to global reporting norms requiring broader consultation of stakeholders and transparency of process. A regional
guideline support committee could harness local capacity to support context appropriate guideline development.
Keywords: clinical practice guidelines, quality, evidence-based, alignment
* Correspondence: Tamara.kredo@mrc.ac.za
1South African Cochrane Centre, South African Medical Research Council,
Cape Town, Western Cape, South Africa
Full list of author information is available at the end of the article
Kredo et al. Health Research Policy and Systems 2012, 10:1
http://www.health-policy-systems.com/content/10/1/1
© 2012 Kredo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Introduction
Clinical practice guidelines bridge the gap between pol-
icy and practice and should be based on up-to-date,
high quality research findings [1,2]. Reducing the burden
of disease in resource-poor settings relies on the avail-
ability of such evidence-based clinical practice guidelines
[3]. Gaps in these guidelines may impact on the health
of the public they are meant to serve. These omissions
may be a result of opinion-based rather than evidence-
based guidance; recommendations from guideline devel-
opment groups with undisclosed conflicts of interest; or
poor planning for implementation of a guideline [4-8].
There is little data regarding the quality and content of
guidelines in Southern Africa, a region facing serious
health issues including poorly contained communicable
diseases, increasing non-communicable diseases and
under-resourced, often poorly managed health systems.
This demands increasing attention from both develop-
ment agencies and researchers to support research
aimed at strengthening guidelines and policy [9].
Several guideline appraisal tools have been developed
to assess the quality of guidelines [10]. Of these, the
Appraisal of Guidelines for Research and Evaluation
(AGREE) tool has been validated and is most widely
accepted [11-13]. None of the available instruments
assesses the clinical content of the guideline or the qual-
ity of the supporting evidence [10]. It is important to
develop methodology for assessing alignment of pub-
lished guidelines with current best evidence.
Our project aimed to evaluate clinical practice guidelines
(CPGs) from the Southern African Development Commu-
nity (SADC) member states, for priority diseases, with
respect to availability, quality and alignment with current
reference guidelines. This study formed part of a larger pro-
gramme, the Southern African Regional Programme on
Access to Medicines (SARPAM) for harmonising CPGs and
essential medicine lists for reforming regional procurement.
Methods
Prioritising guidelines
We considered two issues: firstly, priority diseases should
be representative of the following key components: adult
& paediatric conditions; communicable & non-commu-
nicable diseases; chronic and acute onset diseases; mater-
nal health; hospital-based & primary health care
conditions. Secondly, time and feasibility limited our
selection to five diseases. The following conditions were
prioritised by the SARPAM study team: HIV in adults;
malaria in children and adults; essential hypertension in
primary care; pre-eclampsia; and diarrhoea in children.
Search strategy for guidelines
A public health clinician used an electronic search and
e-mail enquiry strategy to obtain the CPGs for each
SADC country: Angola, Botswana, the Democratic
Republic of Congo (DRC), Lesotho, Malawi, Mauritius,
Mozambique, Namibia, Seychelles, South Africa, Swazi-
land, United Republic of Tanzania, Zambia and
Zimbabwe. The search strategy incorporated possible
document and disease terms which were added to the
country names (Table 1). Medline and Google were
searched using an iterative approach. We contacted
Ministries of Health via the SADC secretariat. Only
English language guidelines were accepted for this
evaluation.
AGREE II instrument
Two reviewers (TK, AG) independently evaluated the
global quality of the five CPGs for each of the SADC
states and the reference guidelines using AGREE II.
This tool is a recently revised and validated version of
the AGREE instrument [14-18]. AGREE II contains 23
key quality items categorised in six domains scored with
a 7-point Likert scale. Standardised guideline domain
scores were calculated by summing scores of individual
items and standardising the total as a percentage of the
maximum possible score for that domain. The six
domain scores are independent and were not aggregated
into a single quality score. Uncertainties in the applica-
tion of AGREE II were resolved in consultation with a
third investigator (NS). We used Microsoft™ Excel to
record the scores. As the data was nonparametric, we
calculated a median (range) for each domain across
countries to provide overall results.
Alignment with reference standard guidelines
and expert opinion
We invited one South Africa-based content expert for
e a c ho ft h ef i v ep r i o r i t ya r e a st og i v ei n p u to nt h i sp r o -
ject. The current gold standard reference guideline for
each topic was identified in consultation with the con-
tent expert [19-26]. The key items of evidence that
should appear in a current guideline on that topic were
then extracted (TK) and the list judged and summarised
by the relevant content expert. These lists represent the
recommendations against which alignment with current
best evidence could be checked with the in-country
guideline. The list of recommendations from each of the
reference guidelines was assigned a point score accord-
ing to the number of recommendations that should be
present to indicate alignment with the reference guide-
line. For example, 25 key items were identified for HIV
guidelines from the WHO 2010 guidelines for the man-
agement of HIV/AIDS in adults and adolescents(19); all
current HIV management guidelines should include
these and would score 100% if all 25 points were identi-
fied (Table 2; tables for list of recommendations for all
reference guidelines are available on request). All
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the recommendations list. There were no specific
weightings for the individual recommendations, as each
item is considered a key item for inclusion in current
guidelines on those topics. For each of the five diseases,
we summarised the concordance of the CPGs using a
percentage score and noted any differences.
Results
Search results
The search was conducted between June and October
2010, including feedback from a SADC secretariat meet-
ing in September 2010. The MEDLINE search yielded
no results. Using Google™ and personal contacts the
search yielded 30 guidelines from 13 SADC states
(Table 3). The publication dates of the available guide-
lines ranged from 2003 to 2010. HIV guidelines were
available from 13 of the 14 states; three were in lan-
guages other than English. Malaria treatment guidelines
were available from 13 of the states, two were not in
English, leaving 11 evaluable for this review, three of
which were sections within other CPGs. Hypertension
guidelines were available from nine countries, only two
of which were disease-specific guidelines (South Africa
and Mauritius)[27]. We did not locate guidelines dedi-
cated to management of diarrhoea in children or pre-
Table 1 Search terms used for finding clinical practice guidelines within SADC
Search concepts Search terms
Medical terms HIV; AIDS; ART; ARV; HAART; Anti-retroviral treatment/therapy; Communicable disease/s
Malaria
Diarrhoea; acute; paediatric; child/ren
Hypertension: cardiovascular disease; CVD
Pre-eclampsia: hypertension; pregnancy
Countries Angola, Botswana, The Democratic Republic of Congo, Lesotho, Malawi, Mauritius, Mozambique, Namibia, Seychelles, South
Africa, Swaziland, United Republic of Tanzania, Zambia and Zimbabwe
Clinical practice
guidelines
Standard treatment guideline/s; STG/s; Standard Treatment; Treatment; Treatment guideline/s
Essential medicine
lists
Essential medicine list; EML; Essential drug list; EDL; Central medical store; procurement list; CMS; Medicine procurement list
Ministries of health Department of Health; DOH; Ministry of Health; MOH; National Aids Commission; Aids Commission; NAC
Table 2 Key recommendations from the reference guideline for the management of HIV in adults
WHO 2010 Details Points
Recommendation 1 When to start - CD4 count < 350
- WHO Clinical stage 3 and 4 irrespective of CD4 count
2
Recommendation 2 What to start - AZT+3TC +EFV
- AZT+3TC+NVP
- TDF+3TC/FTC+EFV
- TDF+3TC/FTC+NVP
4
Recommendation 3 ART for HIV/TB - Start ART in all patients with TB
- Start TB treatment first
- Prefer EFV
- Start ART within 2-8 weeks of starting TB treatment
- If CD4 count < 200, start ART within 2 weeks
5
Recommendation 4 ART for HIV/Hep B - Start ART in all patients who require treatment for their Hepatitis B
- Start TDF and 3TC/FTC
2
Recommendation 5 ART for pregnancy - Start ART in all pregnant women if CD4 count < 350
- Start ART in all women with clinical stage 3 or 4 disease irrespective of CD4 count
- AZT preferred in pregnancy
- EFV or NVP can be used
- Do not start EFV in first trimester
6
Recommendation 6 When to switch -
(note: if VL 5000 or less,
will be accepted e.g. 1000)
- VL > 5000copies/mL on at least two occasions
- Use CD4 count if VL not available
2
Recommendation 7 Second line ART
(note: if any one of the
protease inhibitors
included, will accept)
- Boosted PI + 2 NRTIs recommended
- Atazanavir/ritonavir or Lopinavir/ritonavir or darunavir/ritonavir recommended
- If TDF used in first line, use AZT/D4T next
- AND if AZT/D4T used in first line, use TDF in second line
4
ART = antiretroviral therapy; TB = tuberculosis; Hep B = hepatitis B; VL = viral load; PI = protease inhibitor; NRTIs = nucleoside reverse transcriptase inhibitors;
TDF = tenofovir; AZT = zidovudine; D4T = stavudine; EFV = efavirenz; NVP = nevirapine
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CPGs for these diseases in seven member states for the
former condition and eight member states for the latter.
Summary of AGREE II findings
We present the results according to diseases (Table 4).
Matrices are shown which report the intersection of
AGREE II by domain and alignment with best evidence
(Figures 1, 2, 3, 4 and 5). AGREE II evaluation of the
reference guidelines is shown in Figure 6.
HIV/AIDS
Of the available HIV guidelines, most were disease-speci-
fic guidelines, except that from Seychelles, which had an
abbreviated guideline on HIV management, forming part
of the larger primary care CPG. Two of the guidelines
were in the process of being revised after the release of
the recent WHO 2010 guideline (Table 3) [19]. The
‘clarity and presentation’ and ‘scope and purpose’
domains scored highest with median scores of88% (range
33-94) and 57% (range 19-78) respectively across all
countries. ‘Rigour of development’ and ‘editorial indepen-
dence’ were most poorly reported scoring a median score
of 16% (range 6-30) and 4% (range 0-29) respectively.
Malaria
The ‘scope and purpose’ and ‘clarity and presentation’
domains scored highest, median scores of 71% (range
Table 3 SADC member state guidelines and the reference standard guidelines
SADC
countries
HIV therapy in
adults
Malaria therapy in
adults and
children
Diarrhoea
therapy in
children
Hypertension
therapy in primary
care
Pre-eclampsia therapy Primary care
clinical practice
guideline
iv
Angola N/A
i N/A N/A N/A N/A N/A
Botswana 2008
ii 2007 N/A N/A N/A N/A
Democratic
Republic of
Congo
2005 (French)
iii 2005 (French) N/A N/A N/A N/A
Lesotho 2010 draft N/A N/A N/A N/A 2005
Malawi 2008 N/A N/A N/A N/A 2009
Mauritius 2009 (French) ?date N/A ?date N/A N/A
Mozambique 2009
(Portuguese)
2006 (Portuguese) N/A N/A N/A N/A
Namibia 2009 2005 N/A N/A N/A 2010
Seychelles N/A N/A N/A N/A N/A 2003
South Africa 2010 2009 N/A 2006 N/A 2008
Swaziland 2006 2009 N/A N/A N/A N/A
Tanzania 2005 2006 N/A N/A N/A 2007
Zambia 2007 N/A N/A N/A N/A 2008
Zimbabwe 2010 draft N/A N/A N/A N/A 2006
Standard
reference
guideline
World Health
Organization,
2010
19
World Health
Organization,
2010
20
World Health
Organization,
2005
22,23
National Institute for
Clinical Excellence
2004
24-26
Royal College of
Obstetricians
Gynaecologists, 2006
21
i N/A indicates that the guideline was not available during the search period
ii Dates of publication indicated where was available. Where date was not clear we have indicated this with ‘?date’
iii The language of the guideline-if other than English-is indicated in brackets
iv Primary care guidelines were used to assess alignment when no disease-specific guideline existed
Table 4 Aggregated AGREE II Scores across diseases [median(range)]
Priority diseases Domains of AGREE II
Scope and
purpose
Stakeholder
involvement
Rigor of
development
Clarity and
presentation
Applicability Editorial
independence
HIV (n = 10) 57(19-78) 43(22-58) 16(6-30) 88(33-94) 22(0-58) 4(0-29)
Malaria (n = 11) 71(19-89) 38(6-53) 20(6-32) 88(17-97) 15(0-52) 0(0-25)
Pre-eclampsia (n = 8) 58(31-83) 36(22-61) 14(5-20) 75(36-89) 10(0-27) 0(0-25)
Diarrhoea in children (n
=7 )
58(25-83) 36(22-58) 14(6-20) 83(42-100) 10(0-27) 4(0-25)
Hypertension (n = 9) 75(39-92) 42(22-64) 11(6-44) 81(53-97) 10(0-42) 4(0-50)
Overall 58(19-92) 39(6-75) 14(5-44) 83(17-100) 10(0-58) 0(0-50)
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and ‘editorial independence’ scored poorly, median 15%
(range 0-52) and 0% (range 0-25) respectively.
Pre-eclampsia
Eight guidelines were evaluated, including the 2010 draft
version of the Namibian CPG. The lowest score was seen
for the ‘editorial independence’ domain, median 0%
(range 0-25) and the highest score was seen in the ‘clarity
and presentation’ domain median 75% (range 36-89).
Diarrhoea in children
Domains ‘scope and purpose’, ‘stakeholder involvement’
and ‘clarity and presentation’ received highest scores;
the lowest score was seen for editorial independence
median 4% (range 0-25).
Hypertension in adults
The median score for the domain on ‘clarity and presen-
tation’ was 81% (range 53-97), and the ‘scope and pur-
pose’ median score was 75% (range 39-92), however the
Figure 1 Matrix of AGREE II and alignment with evidence-HIV guidelines within SADC.
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independence’ scoring lowest, median 4% (range 0-50).
Alignment of CPGs with reference standards
Key recommendations from the reference guidelines
were identified with input from experts in the respective
fields.
HIV/AIDS
The Zimbabwe (2010) and Lesotho (2010) guidelines,
both in draft form, were best aligned with current evi-
dence-based guidelines and expert opinion, achieving >
80% alignment (Figure 1). Older guidelines, such as that
from Tanzania (2005), were not well aligned and pre-
sented out-dated recommendations such as the use of
Figure 2 Matrix of AGREE II and alignment with evidence-Malaria guidelines within SADC.
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line from Zambia (2007), achieved good alignment
despite having been published prior to the current
WHO recommendations. This guideline made provi-
sions for recommending the antiretroviral Tenofovir
prior to, but in anticipation of, its availability for first-
line therapy in the country.
Malaria
The five malaria guidelines that were part of a larger
primary care CPG were limited in their scope and gen-
erally did not provide comprehensive management
advice (Figure 2). Older primary care CPGs were less
likely to be in-line with current evidence and tending to
score lower in their alignment (Lesotho 2005, Seychelles
Figure 3 Matrix of AGREE II and alignment with evidence-Pre-eclampsia guidelines within SADC.
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land (2009) were best aligned with current evidence-cer-
tain recommendations that differed from reference
standard advice were justified due to local cost or
regulatory constraints, rather than lack of adherence to
best standards (e.g. use of parenteral quinine rather than
artesunate in South Africa where the drug is not yet
registered by the National Regulatory Authority).
Figure 4 Matrix of AGREE II and alignment with evidence-Childhood diarrhoea guidelines within SADC.
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Most guidance regarding the management of pre-
eclampsia was brief, scoring poorly overall. Malawi
(2009) was most recently published and was current
in its recommendations and scored above 50%
(Figure 3).
Diarrhoea
Diarrhoea management has not changed significantly in
the recent years and as such, most CPGs produced after
the WHO publication in 2005 (22,23) had fair concordance
with recommendations, including the use of zinc in all
guidelines. Zimbabwe (2006), South Africa (2008) and
Malawi (2009) scored 80% alignment (Figure 4).
Hypertension
Two countries with dedicated hypertension guidelines,
South Africa (2006) and Mauritius (unknown date),
scored best in their alignment with current best evi-
dence [27] (Figure 5). The remaining primary care
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Figure 5 Matrix of AGREE II and alignment with evidence-Primary care hypertension guidelines within SADC.
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recommendations hence scoring poorly.
Discussion
To our knowledge this is the first study to report on the
availability and appraisal of quality and content of clini-
cal guidelines for five priority diseases within the SADC
region. Of the available guidelines overall scores were
poor using the AGREE II assessment-particularly with
respect to rigour of development, applicability and edi-
torial independence. Alignment with best evidence was
highly variable, with better scores for guidelines that
were more recently published and those that were dis-
ease-specific rather than sections within larger primary
health care CPGs.
Summary of main findings
HIV and malaria were most likely to have disease-speci-
fic guidelines which may reflect the global funding
streams and political impetus targeting these conditions.
The other priority diseases occupied sections within lar-
ger primary care CPGs. Our review found that the sec-
tions within other manuals that we evaluated were not
comprehensive and provided incomplete guidance and
were less likely to be up-to-date. Overall, the ‘scope and
purpose’ and ‘clarity and presentation’ domains of the
AGREE II tool were reported most comprehensively.
However, the purpose, health question and target users
were not explicitly described. Rather, the information
was incorporated within the introduction and foreword
sections and required extraction in order to identify the
scope and objectives.
Most documents employed clear and consistent meth-
ods for identifying key recommendations, such as flow
diagrams, tables and highlighted text, making the docu-
ments accessible for end-users and resulting in good
scores in ‘clarity and presentation’.T h ev a l u eo ft h e
clarity and presentation hasb e e nq u e s t i o n e da si td o e s
not strictly reflect the internal and external validity of a
guideline document [28]. However, the usability of a
guideline may impact on the applicability of the docu-
ment. Target-users are not necessarily trained to discri-
minate on the quality of the guideline, but may be
encouraged to use it if simple to navigate and apply [29].
The remaining four domains scored poorly across all
diseases. The guidelines described the ‘stakeholder invol-
vement’ of multidisciplinary professional groups; how-
ever, little was reported about the contribution of
primary-care doctors and target patients. This is increas-
ingly recognised as important for assuring that guide-
lines represent the needs of both the target users and
patients. Involving these groups in the guideline devel-
opment process, for example by pre-testing the guide-
line, or evaluating and incorporating preferences and
values, may aid in securing the successful implementa-
tion of the guideline [30,31].
Figure 6 AGREE II scoring for reference guidelines.
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ment’ scored poorly [12]. A minority of guidelines pro-
vided references to the primary data and despite this
many guidelines were highly aligned with current evi-
d e n c e( F i g u r e s1 ,2 , 3 ,4a n d5 ). A plausible explanation
is that the data required to evaluate this domain may
exist in supporting documentation, such as appendices,
which our search failed to locate. In addition, many of
the SADC guidelines base their recommendations on
other reference guidelines, such as WHO publications.
Within SADC there may be members that have the
capacity to appraise, synthesise and apply current evi-
dence but generally it is accepted that few SADC coun-
tries are currently equipped with the necessary technical
and financial resources. Despite this, had the guidelines
we assessed clearly referenced their source guideline,
they should have scored higher in this domain. In future
similar evaluations, it may be prudent to augment the
‘rigour of development’ domain to clearly interrogate
t h es o u r c eo ft h eg u i d e l i n e sd o c u m e n t ,i n c l u d i n g
whether it is based on another reference guideline.
Many of the guideline documents we evaluated indi-
cated that there would be a process for updating but
none were explicit in their methods or the timing of
updates. An important finding from this report is the
lag between revisions of some of the guidelines with the
result that the recommendations are no longer informed
by current evidence potentially posing a risk to public
health.
The methods necessary to successfully implement the
guidelines, were not clearly delineated, hence the low
scoring ‘applicability domain’. Facilitators and barriers to
applying the guidelines should be described to support
implementation. The process of defining facilitators and
barriers to application should be integrated early in the
guideline development process and include professionals
proficient in implementation strategies [29].
The low score in the ‘editorial independence’ domain
reflects the poor reporting of potential conflicts of inter-
est of stakeholders and the potential influence of fun-
ders in the guideline development process. Although the
absence of these declarations does not necessarily imply
that inappropriate influences guided the final recom-
mendations, the presence of such declarations ensures
that a guideline can be considered trustworthy [8,13,32].
Higher alignment scores were attained when guide-
lines were dedicated to a specific illness as seen with the
malaria, HIV and hypertension guidelines. Gaps in the
key recommendations occurred when the guidelines
were out-of-date, occurring more frequently in the pri-
mary care CPGs. Pre-eclampsia scored poorly for align-
ment-indicating that the primary care CPGs we
evaluated did not reflect current evidence. This condi-
tion requires hospital-based care and we did not identify
any secondary or tertiary hospital guidelines during this
r e v i e w .G o o da l i g n m e n tw a sa c h i e v e di ng u i d e l i n e s
despite poor scores in the ‘rigour of development’
domain-indicating a possible mismatch of the tool with
the local practice of basing guidelines on WHO or
equivalent high quality guidelines.
Agreement with previous research
A systematic review evaluating 42 guideline appraisal
studies, including 626 guidelines, between 1988 and
2007 using the AGREE tool found similar distributions
of low and high scores, supporting the notion that the
domains within the guidelines that require improvement
are similar despite disease or region [12]. Our scores for
rigour of development, editorial independence and
applicability were substantially lower than those
described-indicating areas that require particular atten-
tion for future guideline development within SADC.
Our study further highlights the need for support to
improve the quality of guidelines by implementation of
current normative standards of reporting within guide-
lines such as those developed by established guideline
developers [33-35].
Strengths and limitations
We were mandated by the SADC Secretariat Pharma-
ceuticals Programme and therefore received cooperation
from the ministries within the member states to assist
with locating the relevant guidelines. We have attempted
to address the research-knowledge gap by communicat-
ing a technical summary of the results to the SADC
secretariat with specific recommendations for improving
the availability, content and quality of CPGs within
SADC. Although the AGREE II tool has been adopted
widely as the reference tool to be used to evaluate
guideline quality, this is the first time, to our knowledge,
that it has been systematically applied across several dis-
eases in a number of resource-constrained countries in
Africa. This study can therefore contribute to a valida-
tion of the AGREE II tool and support uptake in our
setting. The assessment of the alignment of the contents
of the CPGs in this review was conducted with both
published normative standard guidelines, such as WHO
guidelines, and the input from experts in the respective
fields.
We did not locate all relevant documents given the
absence of a central or country-level repository. The
outstanding documents would be required to provide a
representative baseline analysis for SADC. The guide-
lines we evaluated included a combination of disease-
specific guidelines and sections within larger primary
care manuals. These guidelines may not lend themselves
to be pooled in analysis, but do provide a true reflection
of current guidance of the management of the included
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ing the number of reviewers increases validity [11,19].
Cost and time constraints dictated the feasible number
of content experts and reviewers for this evaluation.
There is currently no validated method for assessing
alignment with evidence; therefore we used a method
that will need future review to assess validity. Lack of
timely translation prevented us from reviewing the
guidelines from French- and Portuguese-speaking coun-
tries. This should be addressed in a future evaluation.
The overall appraisal of quality of the guidelines would
be enhanced by supplementary consultation and inter-
view-based data collection with ministries, giving parti-
cular attention to guideline development processes and
strategies and the roles of various members of the min-
istries of health, scientists and technical experts in for-
mulating the guidelines [10]. Although the AGREE II
tool may be applied across regions and settings, our
experience suggests that ‘rigour of development’ domain
may have scored more poorly than warranted, as the
majority of SADC guidelines rely on guidance from the
WHO, and therefore do not reference primary research
as the domain requires. For this reason we recom-
mended that this domain be amended for future evalua-
tions for use in our setting.
What have we learned?
It is important that gaps in the availability of CPGs be
identified and addressed. A repository of all guidelines
in an accessible database will facilitate access for all
SADC member states. It will facilitate cataloguing of
guidelines and enable identification of those that may be
relevant but missing or out-of-date. This could be done
in collaboration with organisations such as the Guide-
line International Network [36].
There may be value in creating a SADC guideline sup-
port committee, through the SADC Pharmaceutical Pro-
gramme, to assist all member states to adapt, maintain
and update in-country guidelines of high standard [37].
This will facilitate that expertise in guideline develop-
ment be shared. This committee may enlist expertise in
reviewing current evidence with regards its applicability
and generalisability to local healthcare needs. Such a
committee should include, amongst others, the following
relevant stakeholders-content experts; funders; policy
makers; public health professionals; physicians, nurses
and pharmacy staff; patient representative groups and
an external review committee. Collaboration with
experts in the field of guideline development could sup-
port capacity development and aid the process of brid-
ging research and practice.
The value of this review has been to identify specific
gaps in the quality and content of the guidelines within
SADC. There is increasing awareness that the transfer
of research evidence into policy and practice is a com-
plex issue, sensitive to the context of each country. In
order to inspire confidence in the quality and evidence-
base of guideline recommendations and in the transpar-
ency of the development process, each newly developed
or updated guideline should adhere to the recom-
mended reporting norms currently in use globally.
Non-standard abbreviations
CPG: clinical practice guideline; AGREE: Appraisal of
Guidelines for Research and Evaluation.
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